Is metformin an SGLT2 inhibitor

Lactate and ketoacidosis during therapy with metformin and dapagliflozin

1. Merck Serono: Product Information "Glucophage 500 mg / 850 mg / 1000 mg film-coated tablets". Status: January 2017.

2. National Care Guideline "Therapy of Type 2 Diabetes", long version: 1 edition, version 4; ÄZQ, August 2013. Last changed: November 2014.

3. Astra Zeneca GmbH: Technical information "Forxiga® 5 mg film-coated tablets; Forxiga® 10 mg film-coated tablets". Status: April 2017.

4. AstraZeneca GmbH: Information for professionals "Xigduo® 5 mg / 850 mg film-coated tablets; Xigduo® 5 mg / 1000 mg film-coated tablets". Status: April 2017.

5. Vecchio S, Giampreti A, Petrolini VM et al .: Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy. Clin Toxicol (Phila) 2014; 52: 129-135.

6. Daul K, Kribben A, Daul A: [P012] Significance of metformin as a causal factor in metformin-associated lactic acidosis. Consequences for diagnosis, therapy and prevention. Internist (Berlin) 2016; 57 (Suppl. 1): S12-13.

7. Cohen RD, Woods HF: Clinical and Biochemical Aspects of Lactic Acidosis. Oxford, London, Edinburgh, Melbourn: Blackwell Scientific Publications, 1976.

8. Protti A, Fortunato F, Monti M et al .: Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care 2012; 16: R75.

9. Renda F, Mura P, Finco G et al .: Metformin-associated lactic acidosis requiring hospitalization. A national 10 year survey and a systematic literature review. Eur Rev Med Pharmacol Sci 2013; 17 Suppl 1: 45-49.

10. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; Issue 4: CD002967.

11. Kajbaf F, Lalau JD: The criteria for metformin-associated lactic acidosis: the quality of reporting in a large pharmacovigilance database. Diabet Med 2013; 30: 345-348.

12. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ: Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36: 376-382.

13. Peters AL, Buschur EO, ​​Buse JB et al .: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687-1693.

14.AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Lilly Deutschland GmbH, Janssen-Cilag GmbH: Information letter Risk of diabetic ketoacidosis during treatment with SGLT2 inhibitors (Invokana® (canagliflozin), Vokanamet® (canagliflozin / metformin), Forxiga® (dapagliflozin), Xigduo® (dapagliflozin / metformin), Jardiance® (empagliflozin), Synjardy® (empagliflozin / metformin)). Information letter dated July 9, 2015.

15. Candelario N, Wykretowicz J: The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxf Med Case Reports 2016; 2016: 144-146.

16. Gelaye A, Haidar A, Kassab C et al .: Severe ketoacidosis associated with canagliflozin (Invokana): a safety concern. Case Rep Crit Care 2016; 2016: 1656182.

17. Bader N, Mirza L: Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type 1 diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin. Pak J Med Sci 2016; 32: 786-788.

18. Burke KR, Schumacher CA, Harpe SE: SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature. Pharmacotherapy 2017; 37: 187-194.

19. Pujara S, Ioachimescu A: Prolonged ketosis in a patient with euglycemic diabetic ketoacidosis secondary to dapagliflozin. J Investig Med High Impact Case Rep 2017; 5: 2324709617710040.

20. Federal Institute for Drugs and Medical Devices (BfArM): Database of adverse drug effects:

21. Freichel M, Mengel K: Antidiabetics. In: Schwabe U, Paffrath D (ed.). Drug Ordinance Report 2016. Berlin, Heidelberg: Springer-Verlag, 2016; 301-318.